Kurzfassung

In the context of this multinational, multicenter, randomized, anti-Paclitaxel, controlled, clinical trial, the efficacy of MK-3475 and Paclitaxel as a second-line therapy in patients with advanced adenocarcinoma of the stomach will be assessed. The procedure and the further details of the clinical trial are carried out according to test protocol 061. The planned number of according to protocol completed patients in this center is expected to be 5.
The investigations are expected to begin in...In the context of this multinational, multicenter, randomized, anti-Paclitaxel, controlled, clinical trial, the efficacy of MK-3475 and Paclitaxel as a second-line therapy in patients with advanced adenocarcinoma of the stomach will be assessed. The procedure and the further details of the clinical trial are carried out according to test protocol 061. The planned number of according to protocol completed patients in this center is expected to be 5.
The investigations are expected to begin in the second quarter of 2015; The recruitment time is expected to end in the third quarter of 2017. The clinical trial is expected to finish at the end of the third quarter of 2018.
 » weiterlesen» einklappen